ABSTRACT
Background:
Gastroesophageal reflux disease (
GERD) presents in various ways in terms of symptoms and severity. This study was conducted to assess the severity of
GERD patients and to evaluate the effect of itopride and
domperidone on symptoms and severity of
GERD.
Methods:
A
single-blind study was carried out in 70
patients. Group A (n=35)
patients were kept on itopride
therapy, 50 mg thrice a day before
meal. Group B (n=35)
patients were kept on
domperidone therapy, 10 mg thrice a day before
meal.
Patients of both groups were given
rabeprazole, 20 mg once a day for hyperacidity.
Patients served their own control. Each
patient was followed-up at 2 weeks interval up to 8 weeks.
Results:
The most common symptom was
heartburn, present in 95.71%
patients. Regurgitation was the next most common symptom (65.71%). The most common lesion seen endoscopically (according to Savary Miller
classification) was grade I (38.57%). In 24.29%
patient, only symptoms of
GERD were present without any endoscopically visible mucosal
injury. At the end of 2, 4, 6, and 8 weeks, relief of symptoms was more with a combination of itopride and
rabeprazole in comparison to the combination of domperidane and
rabeprazole, but the difference was statistically insignificant. Healing rate at the end of 4th and 8th week was slight better with a combination of itopride and
rabeprazole, but the difference again was statistically insignificant.
Conclusion:
Combination of itopride and
rabeprazole showed insignificantly better results, both symptomatically and endoscopically in comparison to the combination of
domperidone and
rabeprazole.